Dr. Andreas Jenne

SciRhom GmbH / benannt als Vertretung für das BMWi

Andreas Jenne is a serial entrepreneur with more than 20 years of executive management experience in the life sciences industry. He is currently managing director of SciRhom, a biotech start-up developing antibodies for the treatment of autoimmune diseases. His career includes CEO positions at Kinaxo Biotechnologies (a proteomics service provider sold to Evotec in 2011), NEO New Oncology (a cancer diagnostics company acquired by Siemens Healthcare in 2016), and RSP Systems, a medical device company focusing on non-invasive diagnostics. Andreas holds a PhD in chemistry from the Ludwig-Maximilians-University in Munich.